(102 days)
Not Found
No
The summary describes a traditional hip implant system with no mention of AI/ML in its design, function, or testing.
Yes
The device is a medical implant designed to replace failed or diseased hip joints, aiming to restore function and alleviate symptoms, which aligns with the definition of a therapeutic device.
No
The HELICON™ Hip System is a prosthetic device for total hip arthroplasty, which is a treatment, not a diagnostic procedure. Its components include a femoral stem, head, and acetabular shell, all designed to replace damaged hip joints.
No
The device description clearly outlines physical components like a femoral stem, femoral head, acetabular shell, and bone screws, which are hardware.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for total hip arthroplasty, which is a surgical procedure to replace a damaged hip joint. This is a treatment, not a diagnostic test performed on samples from the body.
- Device Description: The device is a hip prosthesis, consisting of physical components like a femoral stem, head, insert, and shell. These are implants used within the body, not reagents or instruments used to analyze biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting specific markers, or providing diagnostic information about a patient's condition based on in vitro testing.
The device is clearly described as a surgical implant for replacing a joint, which falls under the category of medical devices used for treatment, not diagnosis.
N/A
Intended Use / Indications for Use
The HELICON™ Hip System is designed for total hip arthroplasty.
The indications for use are:
- A. Significantly impaired joints resulting from rheumatoid, osteo, and post-traumatic arthritis.
- B. Revision of failed femoral head replacement, cup arthroplasty or other hip procedures.
- C. Proximal femoral fractures.
- D. Avascular necrosis of the femoral head.
- E. Non-union of proximal femoral neck fractures.
- F. Other indications such as congenital dysplasia, arthrodesis conversion, coxa magna, coxa plana, coxa vara, coxa valga, developmental conditions, metabolic and tumorous conditions, osteomalacia, osteoporosis, pseudarthrosis conversion, and structural abnormalities
The HELICON™ hip stem is indicated for cementless use. The HELICON™ acetabular shell component is indicated for cemented or cementless use.
Product codes (comma separated list FDA assigned to the subject device)
LPH
Device Description
The HELICON Hip System (HHS) is a porous-coated, semi-constrained, hip prosthesis designed for either primary or revision hip arthroplasty. The HHS includes a femoral stem, a CoCr femoral head, non-crosslinked UHMWPE insert, acetabular shell and bone screws.
The HHS stem is a monolithic, titanium alloy, tapered hip stem available with a proximal CPTi plasma porous coating. The stem has a dual wedge geometry and is available in both standard and 7mm lateral offsets in sizes ranging from 7.5mm to 24mm. The stems feature a neck shaft angle of 135° and a 12/14 Morse taper trunnion. HHS stems are compatible with the HHS CoCr femoral head and HHS acetabular insert. The HHS CoCr head is highly polished and available in multiple offsets and diameters (22, 28, and 32mm). The HHS acetabular components include a titanium alloy shell and a mating UHMWPE insert. The shell is a hemispherical design, is available with or without screw holes, and employs a CPTi beaded, porous coating. The UHMWPE insert is available in 20° hooded or nonhooded (neutral) configurations in inner diameters of 22, 28, and 32mm. Titanium alloy bone screws are available for additional fixation.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Hip
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
COI provided rights to reference their 510(k)s and supporting performance testing. The HELICON Hip System (HHS) implant components use the identical materials, design construct features (e.g., including locking mechanisms of the polyethylene insert to the metal shell and the exterior coatings) of the predicate components. No changes were made to the predicate components that required additional testing. The HHS implant components were evaluated using a Failure Modes and Effects Analysis (FMEA). No additional nonclinical bench testing was deemed necessary over that used in support of the predicates based on identical design and materials.
Predicate bench testing included distal and proximal stem fatigue testing of the worst-case stem consistent with the "Guidance for Industry and FDA Staff Non-clinical Information for Femoral Stem Prostheses;" Range of Motion analysis; CPTi plasma sprayed and CPTi beaded metallic coating characterization per the "Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Bone Cement;" CPTi plasma spray characterization per the "Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements;" polyethylene insert retention mechanism testing; and bone screw mechanical strength testing. Additionally, modular connection analyses including fretting and corrosion of the metallic femoral heads for compatibility and pin-on-flat testing of the non-crosslinked UHMWPE/CoCr material combination were also performed. Both the CPTi plasma sprayed coating and the CPTi beaded coating characterizations meet the regulatory definition of porous coating for the hip construct per 21 CFR 888.3358.
All of the observed results for the predicate TaperSet Hip System had been found substantially equivalent prior to devices currently marketed. The subject Helicon Hip System is identical in material and design to that of the TaperSet Hip System. Therefore, the subject device is as safe, as effective, and performs at least as safely and effectively as legally marketed predicates.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K922561, K960339, K960156, K960340, K102399, K100933, K020153
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3358 Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis.
(a)
Identification. A hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across the joint. This generic type of device has a femoral component made of a cobalt-chromium-molybdenum (Co-Cr-Mo) alloy or a titanium-aluminum-vanadium (Ti-6Al-4V) alloy and an acetabular component composed of an ultra-high molecular weight polyethylene articulating bearing surface fixed in a metal shell made of Co-Cr-Mo or Ti-6Al-4V. The femoral stem and acetabular shell have a porous coating made of, in the case of Co-Cr-Mo substrates, beads of the same alloy, and in the case of Ti-6Al-4V substrates, fibers of commercially pure titanium or Ti-6Al-4V alloy. The porous coating has a volume porosity between 30 and 70 percent, an average pore size between 100 and 1,000 microns, interconnecting porosity, and a porous coating thickness between 500 and 1,500 microns. The generic type of device has a design to achieve biological fixation to bone without the use of bone cement.(b)
Classification. Class II.
0
TGM Medical, Inc Premarket Traditional 510(k) Notification: HELICON Hip System
Page 1 of 3
| 510(k) SUMMARY | K 111472 | |
|---|---|---|
| Sponsor Name: | TGM Medical, Inc. | |
| 5145 Golden Foothill Parkway, Suite 175 & 180 | ||
| El Dorado Hills, CA 95762 | SEP - 6 20 | |
| 510(k) Contact: | Dennis Crane | |
| Emerson Consultants, Inc | ||
| 12701 Whitewater Drive, Suite 120 | ||
| Minnetonka, MN 55343 | ||
| Phone: 952.374.6012 / Fax: 952.374.6001 | ||
| dennisc@emersonconsultants.com | ||
| Date Prepared: | August 29, 2011 | |
| Trade Name: | HELICON Hip System (HHS) | |
| Common Name: | Porous-coated hip prosthesis for cementless use | |
| Classification Name: | Hip joint metal/polymer/metal semi-constrained porous-coated | |
| uncemented prosthesis (21 CFR 888.3358, Class II device, | ||
| Product Code LPH). |
Device Description:
The HELICON Hip System (HHS) is a porous-coated, semi-constrained, hip prosthesis designed for either primary or revision hip arthroplasty. The HHS includes a femoral stem, a CoCr femoral head, non-crosslinked UHMWPE insert, acetabular shell and bone screws.
The HHS stem is a monolithic, titanium alloy, tapered hip stem available with a proximal CPTi plasma porous coating. The stem has a dual wedge geometry and is available in both standard and 7mm lateral offsets in sizes ranging from 7.5mm to 24mm. The stems feature a neck shaft angle of 135° and a 12/14 Morse taper trunnion. HHS stems are compatible with the HHS CoCr femoral head and HHS acetabular insert. The HHS CoCr head is highly polished and available in multiple offsets and diameters (22, 28, and 32mm). The HHS acetabular components include a titanium alloy shell and a mating UHMWPE insert. The shell is a hemispherical design, is available with or without screw holes, and employs a CPTi beaded, porous coating. The UHMWPE insert is available in 20° hooded or nonhooded (neutral) configurations in inner diameters of 22, 28, and 32mm. Titanium alloy bone screws are available for additional fixation.
Indications for Use:
The HELICON™ Hip System is designed for total hip arthroplasty.
The indications for use are:
- A. Significantly impaired joints resulting from rheumatoid, osteo, and post-traumatic arthritis.
1
TGM Medical, Inc Premarket Traditional 510(k) Notification: HELICON Hip System
Page 2 of 3
- B. Revision of failed femoral head replacement, cup arthroplasty or other hip procedures.
- C. Proximal femoral fractures.
- D. Avascular necrosis of the femoral head.
- E. Non-union of proximal femoral neck fractures.
- F. Other indications such as congenital dysplasia, arthrodesis conversion, coxa magna, coxa plana, coxa vara, coxa valga, developmental conditions, metabolic and tumorous conditions, osteomalacia, osteoporosis, pseudarthrosis conversion, and structural abnormalities
The HELICON™ hip stem is indicated for cementless use. The HELICON™ acetabular shell component is indicated for cemented or cementless use.
Substantial Equivalence:
Technological Characteristics/Substantial Equivalence:
The HHS is equivalent to predicate systems in design geometry, materials, performance testing and indications for use. Consensus Orthopedics, Inc. (COI) licensed their previously cleared hip components to TGM Medical, Inc. The hip components consist of the previously cleared TaperSet Hip System femoral stem (K102399), CoCr femoral heads (K922561, K960339, and K960156), UHMWPE inserts (K922561 and K020153), acetabular shell (K922561) and titanium bone screws (K922561). The HHS hip components therefore have the same technological characteristics to those used in the Consensus Taper Set Hip System. Based on the identical material, characterization data, geometry and mechanical testing, the HHS system is substantially equivalent to legally marketed predicates (Table 2.1).
| 510(k)
Number | Trade Name | 510(k) holder | 510(k)
Release Date |
|------------------|------------------------------------------|-----------------------------|------------------------|
| K922561 | Consensus Total Hip System | U.S. Medical Products, Inc. | 07/21/1993 |
| K960339 | Consensus 22mm CoCrMo Femoral
Head | U.S. Medical Products, Inc. | 02/21/1996 |
| K960156 | Consensus 32mm CoCrMo Femoral
Head | U.S. Medical Products, Inc. | 02/21/1996 |
| K960340 | Consensus Apex Dome Hole Plug | U.S. Medical Products, Inc. | 03/15/1996 |
| K102399 | Consensus TaperSet Hip System | Consensus Orthopedics, Inc. | 12/02/2010 |
| K100933 | CS2 Plus Acetabular Insert | Consensus Orthopedics, Inc. | 10/06/2010 |
| K020153 | Consensus Acetabular Shell, Ti
Coated | Hayes Medical, Inc. | 04/15/2002 |
Table 2.1: Legally marketed devices to which substantial equivalence is claimed:
Non-Clinical Performance Data:
COI provided rights to reference their 510(k)s and supporting performance testing. The HELICON Hip System (HHS) implant components use the identical materials, design construct features (e.g., including locking mechanisms of the polyethylene insert to the metal shell and the exterior coatings) of the predicate components. No changes were made to the predicate components that required additional testing. The HHS implant components
2
TGM Medical. Inc Premarket Traditional 510(k) Notification: HELICON Hip System
Page 3 of 3
-111472
were evaluated using a Failure Modes and Effects Analysis (FMEA). No additional nonclinical bench testing was deemed necessary over that used in support of the predicates based on identical design and materials.
Predicate bench testing included distal and proximal stem fatigue testing of the worst-case stem consistent with the "Guidance for Industry and FDA Staff Non-clinical Information for Femoral Stem Prostheses;" Range of Motion analysis; CPTi plasma sprayed and CPTi beaded metallic coating characterization per the "Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Bone Cement;" CPTi plasma spray characterization per the "Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements;" polyethylene insert retention mechanism testing; and bone screw mechanical strength testing. Additionally, modular connection analyses including fretting and corrosion of the metallic femoral heads for compatibility and pin-on-flat testing of the non-crosslinked UHMWPE/CoCr material combination were also performed. Both the CPTi plasma sprayed coating and the CPTi beaded coating characterizations meet the regulatory definition of porous coating for the hip construct per 21 CFR 888.3358.
All of the observed results for the predicate TaperSet Hip System had been found substantially equivalent prior to devices currently marketed. The subject Helicon Hip System is identical in material and design to that of the TaperSet Hip System. Therefore, the subject device is as safe, as effective, and performs at least as safely and effectively as legally marketed predicates.
3
Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an emblem of an eagle with its wings spread, with three bars across its body.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
TGM Medical. Inc. % Emerson Consultants. Inc. Mr. Dennis Crane 12701 Whitewater Drive, Suite 120 Minnetonka, Minnesota 55343
SEP - 6 2011
Re: K111472
Trade/Device Name: HELICON Hip System (HSS) Regulation Number: 21 CFR 888.3358 Regulation Name: Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis Regulatory Class: Class II Product Code: LPH Dated: August 3, 2011 Received: August 5, 2011
Dear Mr. Crane:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
4
Page 2 - Mr. Dennis Crane
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.html for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Eric Keith
fs Mark N. Melkerson Director Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
1. INDICATIONS FOR USE STATEMENT
K 11472
510(k) Number (if known):
Device Name: HELICON Hip System
Indications for Use:
The HELICON™ Hip System is designed for total hip arthroplasty.
The indications for use are:
- Significantly impaired joints resulting from rheumatoid, osteo, and post-traumatic A. arthritis.
- Revision of failed femoral head replacement, cup arthroplasty or other hip B. procedures.
- Proximal femoral fractures. C..
- D. Avascular necrosis of the femoral head.
- Non-union of proximal femoral neck fractures. E.
- Other indications such as congenital dysplasia, arthrodesis conversion, coxa F. magna, coxa plana, coxa vara, coxa valga, developmental conditions, metabolic and tumorous conditions, osteomalacia, osteoporosis, pseudarthrosis conversion, and structural abnormalities
The HELICON™ hip stem is indicated for cementless use. The HELICON™ acetabular shell component is indicated for cemented or cementless use.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ X (21 CFR Part 801 Subpart D) Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
AND/OR
Concurrence of CDRH, Office of Device Evaluation (ODE)
for M Melkeem
(Division Sign Division signical (Division Sign-Dff)
Division of Surgical, Orthopedic, Orthopedic,
Controlectorerive Devices Division of Surgion in Surgices
and Restorative Devices and Restorative Devices
510(k) Number -